Tonix Pharmaceuticals Added to Russell 3000 and Russell 2000 Indexes
TL;DR
Tonix Pharmaceuticals' inclusion in the Russell 3000® and 2000® Indexes enhances investor visibility and positions the company for growth ahead of TNX-102 SL's potential FDA approval.
Tonix Pharmaceuticals joins the Russell indexes after meeting market cap criteria, a step reflecting its progress toward FDA submission for fibromyalgia treatment TNX-102 SL.
Tonix Pharmaceuticals' advancements in fibromyalgia treatment and antiviral research promise to improve patient quality of life and address critical public health challenges.
Tonix Pharmaceuticals secures a spot in the Russell indexes, marking a milestone as it advances TNX-102 SL for fibromyalgia and explores antiviral therapies.
Found this article helpful?
Share it with your network and spread the knowledge!
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated biopharmaceutical company, has achieved a notable milestone with its inclusion in the Russell 3000® and Russell 2000® Indexes. This inclusion, effective June 30, 2025, is a testament to the company's growing market capitalization and its promising pipeline, particularly the potential FDA approval and launch of TNX-102 SL for the management of fibromyalgia. The Russell indexes are among the most widely used benchmarks for investment portfolios, with approximately $10.6 trillion in assets tied to their performance, highlighting the significance of Tonix's addition to these indexes.
The CEO of Tonix Pharmaceuticals, Seth Lederman, emphasized that this achievement enhances the company's visibility among investors as it moves closer to commercializing its lead product candidate, TNX-102 SL. This product has already completed two statistically significant phase 3 studies for fibromyalgia and has received Fast Track designation from the FDA, underscoring its potential to address a significant unmet medical need. The company is preparing to submit a New Drug Application (NDA) to the FDA this month, a critical step toward bringing TNX-102 SL to market.
Beyond fibromyalgia, Tonix is also developing TNX-102 SL for the treatment of acute stress reaction and has secured a contract with the U.S. Department of Defense for the development of TNX-4200, a broad-spectrum antiviral agent. These developments, coupled with the company's state-of-the-art research and manufacturing facilities, position Tonix as a key player in addressing public health challenges, including pain management and infectious diseases.
The inclusion in the Russell indexes not only reflects Tonix's financial and operational growth but also opens up new opportunities for the company to attract investment and partnerships. For investors and the biotech industry, Tonix's progress and its recognition by the Russell indexes signal the potential for significant advancements in the treatment of fibromyalgia and other conditions, with broader implications for healthcare and public health.
Curated from InvestorBrandNetwork (IBN)
